Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-Stage Renal Disease (ESRD)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Apr 2022 Results evaluating the effect of haemodialysis on doravirine concentrations in people living with HIV undergoing routine haemodialysis, published in the Journal of Antimicrobial Chemotherapy
16 Feb 2022 Results assessing the effect of hemodialysis on doravirine clearance HIV-infected patients undergoing routine hemodialysis, presented at the 29th Conference on Retroviruses and Opportunistic Infections
06 Jul 2021 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com